PURETECH

Serial Number 90811128
733

Registration Progress

Application Filed
Jul 5, 2021
Under Examination
Aug 15, 2023
Approved for Publication
Jun 20, 2023
Published for Opposition
Jun 20, 2023
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Feb 15, 2026 29 days

Trademark Image

PURETECH

Basic Information

Serial Number
90811128
Filing Date
July 5, 2021
Published for Opposition
June 20, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
733
Status Date
Aug 11, 2025
Application
Pending
Classes
005 042

Rights Holder

PureTech Health LLC

16
Address
4th Floor
6 Tide St.
Boston, MA 02210

Ownership History

PureTech Health LLC

Original Applicant
16
Boston, MA

PureTech Health LLC

Owner at Publication
16
Boston, MA

Legal Representation

Attorney
Christina Brown

USPTO Deadlines

Next Deadline
29 days remaining
NOA E-Mailed - SOU Required
Due Date
February 15, 2026
Extension Available
Until August 15, 2026

Application History

38 events
Date Code Type Description Documents
Aug 12, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 11, 2025 EX4G S SOU EXTENSION 4 GRANTED Loading...
Aug 11, 2025 EXT4 S SOU EXTENSION 4 FILED Loading...
Aug 11, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 4, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 3, 2025 EX3G S SOU EXTENSION 3 GRANTED Loading...
Feb 3, 2025 EXT3 S SOU EXTENSION 3 FILED Loading...
Feb 3, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 13, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 13, 2024 EX2G S SOU EXTENSION 2 GRANTED Loading...
Aug 13, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
Aug 13, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 9, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 8, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 8, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 8, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 15, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 20, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 20, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 31, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 15, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 9, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
May 9, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
May 9, 2023 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
May 9, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Nov 16, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 16, 2022 GNRT O NON-FINAL ACTION E-MAILED Loading...
Nov 16, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 6, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 6, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 6, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Aug 30, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 7, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 7, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 7, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 24, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 14, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 8, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
House mark for pharmaceutical compositions as prophylaxis, diagnostics or treatments for human and animal disease and illness, namely infectious diseases, inflammatory disorders, respiratory diseases, cardiovascular diseases, autoimmune disorders, gastrointestinal disorders, cancer, hematological diseases, neurological diseases, hepatic diseases, renal diseases, lymphatic disorders, metabolic disorders, genetic disorders, dermatological disorders, ocular diseases, and orphan diseases and drug delivery agents and formulations consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals and other chemical, synthetic or biologic payloads, in the nature of pharmaceutical compositions to treat the above disorders that can be administered in a range of approaches
Class 042
research and development in the pharmaceutical, biotechnology, and digital medicine fields

Additional Information

Pseudo Mark
PURE TECH

Classification

International Classes
005 042